Part Two: Overcoming The Limitations Of Current LVV Titer Measurement

By Poorni Adikaram, Ph.D., Tyler Frazier, and Timothy Fouts, Ph.D., CSO, at ABL Inc- . and Rebecca Montange, Ph.D, and Brandon Harrell at Sartorius

The rising demand for lentiviral vectors (LVVs) is driving the need for scalable, robust GMP-compliant manufacturing processes. However, accelerating process development is often hindered by the lack of fast and reliable methods for LVV quantification. The Virus Counter® Plus platform (Sartorius), featuring the Virotag® VSVG assay, offers near-real-time, accurate measurement of total particle counts — enabling quicker development of efficient production processes.

In this three-part blog series, scientists from ABL, Inc. explore the limitations of current titer measurement techniques, introduce the Virus Counter Plus platform, and share key findings from a recent collaborative study with Sartorius. This study evaluates how titer results from the new method compare with data from conventional physical and functional assays.